Watchlist Price Alert

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCC · Real-Time Price · USD

1.63

-0.05 (-2.98%)

At close: Jun 16, 2025, 3:59 PM

1.62

-0.61%

Pre-market: Jun 17, 2025, 05:02 AM EDT

-2.98% (1D)

Bid	1.46
Market Cap	115.74M
Revenue (ttm)	39.78M
Net Income (ttm)	-103.28M
EPS (ttm)	-1.48
PE Ratio (ttm)	-1.1
Forward PE	n/a
Analyst	Buy

Ask	1.74
Volume	870,721
Avg. Volume (20D)	1,088,896
Open	1.69
Previous Close	1.68
Day's Range	1.59 - 1.74
52-Week Range	1.08 - 7.66
Beta	2.95

About CCCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CCCC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CCCC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

9 months ago

+13.79%

C4 Therapeutics shares are trading higher after th... Unlock content with Pro Subscription

News

1 day ago · seekingalpha.com

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerabil...

1 month ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.